Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.

Original languageEnglish (US)
Pages (from-to)234-237
Number of pages4
Issue number2
StatePublished - Jan 15 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this